Kerala State Drugs and Pharmaceuticals Limited

Tianda Pharma Announces 2022/23 Interim Results

Retrieved on: 
Friday, November 25, 2022
Cloud, Marketing, COVID-19, D, BD, III, Prescription, Kerala State Drugs and Pharmaceuticals Limited, R, API, Policy, Patient, Heart, 3D, TCM, ID, Tsim Sha Tsui, Research, Central Drugs Standard Control Organisation, Depreciation, Traditional Chinese characters, CMO, Medicine, CDMO, Acquisition, Hong Kong Stock Exchange, Pharmaceutical industry, Fine chemical, Period

HONG KONG, Nov 25, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited ("Tianda Pharma" or "the Group"; stock code: 0455.HK) today announced its interim results for the six months ended 30 September 2022 ("the Period").

Key Points: 
  • HONG KONG, Nov 25, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited ("Tianda Pharma" or "the Group"; stock code: 0455.HK) today announced its interim results for the six months ended 30 September 2022 ("the Period").
  • During the Period, the Group adopted proactive marketing strategy and improved its results notably.
  • The Group has worked hard cultivating the cardiovascular, cerebrovascular and pediatric disease realms and owns unique generic product pipelines.
  • Boasting notable efficacy and competitive price, Tuoping Valsartan capsules, the Group's core product for treating cardio-cerebrovascular disease, has been ranked the No.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Friday, October 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Friday, October 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Tianda Pharmaceuticals Annual Results 2022

Retrieved on: 
Thursday, June 30, 2022
Cloud, Efficiency, Current, Research, COVID, Medicine, R, YOY, Marketing, COVID-19, Growth, Industry, Trust, TCM, CDMO, Rehabilitation, CMO, Awareness, ID, Woman, Contract, Central Drugs Standard Control Organisation, ISO, Technology, Health, No, Certification, CSR, Farmer, Board, Kerala State Drugs and Pharmaceuticals Limited, BD, Medication, Method, Director, Fine chemical, Pharmaceutical industry, Group

HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.

Key Points: 
  • HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.
  • Innovation and R&D made steady progress with R&D expenses increasing 34.7% year on year (YOY) to HK$15.9 million.
  • With cash and cash equivalents of approximately HK$334.0 million as of 31 March 2022, the Group has sufficient financial resources to support its business development.
  • The new R&D and production base located in Jinwan, Zhuhai
    The Pharmaceuticals and medical technologies business revenue reached HK$396.1 million, an increase of 10.7% YOY.

Innocoll Announces Positive Topline Results For XARACOLL® (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Risk, Shanda, Toxicity, Patient, Tremor, Hydrogen chloride, Industry, Anesthetic, Population, Abdominoplasty, Food, Seroma, Methemoglobinemia, Safety, GPC, Blurred vision, Bupivacaine, Colectomy, FDA, Program, Kerala State Drugs and Pharmaceuticals Limited, Headache, Hysterectomy, BMJ, Rash, DO, Hernia, Diffusion, Association, US Foods, Dysgeusia, Liver, Constipation, Publication, Incidence, Back pain, Blood pressure, Pharmaceutical industry, Dentistry, Birth control, Medical device, Fever

This data complements the positive results of XARACOLL in acute post-surgical pain following open inguinal hernia repair in adults, for which XARACOLL is currently approved.

Key Points: 
  • This data complements the positive results of XARACOLL in acute post-surgical pain following open inguinal hernia repair in adults, for which XARACOLL is currently approved.
  • These positive topline Phase 3 clinical trial results will support Innocolls soft tissue surgery development program and its anticipated sNDA application to expand the indications for XARACOLL.
  • We are excited to report the positive results of this Phase 3 clinical trial with XARACOLL.
  • XARACOLL implant releases bupivacaine after placement at the surgical site through diffusion from the porous collagen implant, which dissolves over time.

Tianda Pharma Interim Results 2021

Retrieved on: 
Friday, November 26, 2021
Cloud, Traditional Chinese medicine, Central Drugs Standard Control Organisation, Industry, Acquisition, Jiangxi University of Traditional Chinese Medicine, Health, Medicine, Policy, R, YOY, Marketing, Efficiency, Medication, Prescription, BD, TCM, No, Kerala State Drugs and Pharmaceuticals Limited, Fine chemical

HONG KONG, Nov 26, 2021 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharma or the Group, stock code: 0455.HK) is pleased to announce its interim results for the six months ended 30 September 2021 (the "Reporting Period").

Key Points: 
  • HONG KONG, Nov 26, 2021 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharma or the Group, stock code: 0455.HK) is pleased to announce its interim results for the six months ended 30 September 2021 (the "Reporting Period").
  • Such strong financial position provides the Group with sufficient financial resources to support its steady business development.
  • The Chinese medicine business recorded revenue of HK$58.0 million, representing an increase of 64.2% YOY.
  • The Pharmaceuticals and medical technologies business recorded revenue of HK$174.9 million, representing an increase of 16.6% YOY.

Telix to Collaborate With Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

Retrieved on: 
Tuesday, September 7, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Hospitals, Kettering Health, Telix Pharmaceuticals Limited, KETTERING HEALTH, TELIX PHARMACEUTICALS LIMITED

The MOU outlines the principles of the collaboration between Kettering Health and Telix.

Key Points: 
  • The MOU outlines the principles of the collaboration between Kettering Health and Telix.
  • Telix and Kettering Health plan to work closely with multiple industry leaders, culminating in the rapid implementation of PET MI technologies (imaging and theranostics) into clinical services for patients in the region.
  • As a faith-based, not-for-profit health system, Kettering Health follows in the steps of Jesus to help guide every person to their best health.
  • Kettering College, a division of Kettering Medical Center, is a fully accredited college that specializes in health science education.